Alcon (ALC – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Julien Ouaddour from Bank of America Securities maintained a Buy rating on the stock and has a CHF96.00 price target.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Julien Ouaddour has given his Buy rating due to a combination of factors despite Alcon’s softer start in Q1 FY25. The company’s sales and earnings per share (EPS) were slightly below expectations, with a 2% miss in both areas. This was attributed to challenges in the US market and competitive pressures, particularly in the implantables segment. However, the consumables segment showed resilience with a 6% growth at constant currency, and the company anticipates a positive impact from foreign exchange tailwinds, which should bolster sales figures.
Despite the revised guidance indicating a reduction in core EBIT margin and EPS expectations, Ouaddour maintains a positive outlook on Alcon’s long-term growth potential. The anticipated product launches in the second half of the year are expected to drive growth acceleration. Additionally, the company’s strategic operational actions and recent business developments are projected to offset any negative impacts from tariffs, supporting a strong exit rate for 2026. These factors contribute to Ouaddour’s confidence in maintaining a Buy rating for Alcon.
According to TipRanks, Ouaddour is ranked #2014 out of 9519 analysts.